349 A novel ‘off the shelf’ TCR-NK cell therapy platform for the treatment of solid tumours: development of optimised MAGE-A4 targeting TCR-NK cells for advancement into the clinic

• Ines Cardoso,
• Sylvie Pollmann,
• Luise U Weigand

Affiliations

Ines Cardoso

Zelluna Immunotherapy AS, Oslo, Oslo, Norway

Sylvie Pollmann

Zelluna Immunotherapy AS, Oslo, Oslo, Norway

Luise U Weigand

Zelluna Immunotherapy AS, Oslo, Oslo, Norway